Journal
PLOS ONE
Volume 6, Issue 1, Pages -Publisher
PUBLIC LIBRARY SCIENCE
DOI: 10.1371/journal.pone.0015905
Keywords
-
Categories
Funding
- National Institutes of Health (NIH) [EY019144, EY006311, EY02377]
- Louisiana Cancer Research Consortium
- Xavier University of Louisiana Center for Undergraduate Research
- Model Institutions for Excellence (MIE)-Science, Technology, Engineering and Mathematics (STEM)
- Louisiana Board of Regents, RC/EEP [07-10]
- LSU Health Sciences Center
- Research to Prevent Blindness
- Senior Scientific Investigator Award
- Research to Prevent Blindness, New York, New York
- Louisiana Lions Eye Foundation, New Orleans, Louisian
- Louisiana Board of Regents
- Lions International, United States of America
Ask authors/readers for more resources
Angiogenesis is a hallmark of tumor development and metastasis and now a validated target for cancer treatment. We previously reported that a novel dimer peptide (apoEdp) derived from the receptor binding region of human apolipoprotein E (apoE) inhibits virus-induced angiogenesis. However, its role in tumor anti-angiogenesis is unknown. This study demonstrates that apoEdp has anti-angiogenic property in vivo through reduction of tumor growth in a mouse model and ocular angiogenesis in a rabbit eye model. Our in vitro studies show that apoEdp inhibits human umbilical vein endothelial cell proliferation, migration, invasion and capillary tube formation. We document that apoEdp inhibits vascular endothelial growth factor-induced Flk-1 activation as well as downstream signaling pathways that involve c-Src, Akt, eNOS, FAK, and ERK1/2. These in vitro data suggest potential sites of the apoE dipeptide inhibition that could occur in vivo. This is the first evidence that a synthetic dimer peptide mimicking human apoE has anti-angiogenesis functions and could be an anti-tumor drug candidate.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available